|
Q4 FY2024
As of Dec 31, 2025
|
Q4 FY2023
As of Dec 31, 2024
|
Q4 FY2022
As of Dec 31, 2023
|
Q4 FY2021
As of Dec 31, 2022
|
Q4 FY2020
As of Dec 31, 2021
|
Q4 FY2019
As of Dec 31, 2020
|
Q4 FY2018
As of Dec 31, 2019
|
Q4 FY2017
As of Dec 31, 2018
|
Q4 FY2016
As of Dec 31, 2017
|
Q4 FY2015
As of Dec 31, 2016
|
Q4 FY2014
As of Dec 31, 2015
|
Q4 FY2013
As of Dec 31, 2014
|
Q4 FY2012
As of Dec 31, 2013
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||||
| CURRENT ASSETS: | |||||||||||||
| Cash and cash equivalents | |||||||||||||
| Restricted cash | |||||||||||||
| Short-term deposits | |||||||||||||
| Restricted deposits | |||||||||||||
| Marketable securities | |||||||||||||
| Trade receivables | |||||||||||||
| Prepaid expenses and other current assets | |||||||||||||
| Total current assets | |||||||||||||
| LONG-TERM ASSETS: | |||||||||||||
| Prepaid expenses and other long-term assets | |||||||||||||
| Property, Plant and Equipment, Net | |||||||||||||
| Equity Method Investments | |||||||||||||
| Marketable securities | |||||||||||||
| Long-term assets | |||||||||||||
| Intangible assets, net | |||||||||||||
| Goodwill | |||||||||||||
| Operating Lease, Right-of-Use Asset | |||||||||||||
| Total long-term assets | |||||||||||||
| TOTAL ASSETS | |||||||||||||
| LIABILITIES AND SHAREHOLDERS' DEFICIENCY | |||||||||||||
| CURRENT LIABILITIES: | |||||||||||||
| Trade payables | |||||||||||||
| Employees and payroll accruals | |||||||||||||
| Deferred revenues | |||||||||||||
| Current portion of convertible notes, net | |||||||||||||
| Accrued expenses and other current liabilities | |||||||||||||
| Operating lease liabilities | |||||||||||||
| Total current liabilities | |||||||||||||
| LONG-TERM LIABILITIES: | |||||||||||||
| Convertible Notes Payable, Noncurrent | |||||||||||||
| Deferred revenues | |||||||||||||
| Long-term liabilities | |||||||||||||
| Other long-term liabilities | |||||||||||||
| Operating lease liabilities | |||||||||||||
| Total long-term liabilities | |||||||||||||
| Total liabilities | |||||||||||||
| Commitments and contingencies | |||||||||||||
| SHAREHOLDERS' DEFICIENCY: | |||||||||||||
| Ordinary shares of NIS 0.01 par value - Authorized: 500,000,000 shares at December 31, 2025 and 2024; Issued 67,143,958 and 64,718,465 shares at December 31, 2025 and 2024, respectively; Outstanding: 54,989,523 and 56,107,932 shares at December 31, 2025 and 2024, respectively | |||||||||||||
| Additional paid-in capital | |||||||||||||
| Treasury shares at cost, 12,154,435 ordinary shares as of December 31, 2025 and 8,610,533 as of December 31, 2024 | |||||||||||||
| Accumulated other comprehensive income | |||||||||||||
| Accumulated deficit | |||||||||||||
| Total shareholders' deficiency | |||||||||||||
| TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIENCY | |||||||||||||
| Common stock, par or stated value per share (in USD per share) | |||||||||||||
| Common stock, shares authorized (in shares) | |||||||||||||
| Treasury Stock, Common, Shares | |||||||||||||
| Entity Common Stock, Shares Outstanding | |||||||||||||
| Common stock, shares outstanding (in shares) | |||||||||||||
| Common stock, shares issued (in shares) | |||||||||||||
Loading...